Aromatase inhibitors are a cornerstone of hormone-positive breast cancer treatment, but their impact on bone density and fracture risk presents an ongoing challenge in survivorship care. As more survivors live longer, protecting long-term skeletal health has become a critical component of comprehensive post-cancer management.

In this expert-led session, Mike McClung, MD, FACP, FACE, reviews the mechanisms of AI-associated bone loss and outlines practical, evidence-based approaches to risk assessment, screening, prevention, and treatment. Attendees will gain clarity on current guidelines, emerging research, and clinical strategies to help breast cancer survivors preserve bone strength and reduce fracture risk over time.

This talk is designed for clinicians caring for breast cancer survivors and aligns with a whole-person approach to long-term health after cancer.

Michael McClung, MD, FACP, FACE, is a globally recognized expert in osteoporosis and bone health. As the founding director of the Oregon Osteoporosis Center, he has led groundbreaking research on fracture prevention, bone density, and the role of Menopausal Hormone Therapy (MHT) in skeletal health. Dr. McClung has contributed extensively to international guidelines and continues to educate healthcare providers on evidence-based strategies for osteoporosis management.